The Relationship between Metformin Consumption and Cancer Risk: An Updated Umbrella Review of Systematic Reviews and Meta‑Analyses

Farid Najafi, Fatemeh Rajati, Diana Sarokhani, Maryam Bavandpour, Mehdi Moradinazar

Abstract


Background: Considering that metformin is widely used in the treatment of diabetes, and its protective role against various malignancies, the strength and validity of the available evidence from related systematic reviews and meta-analysis were evaluated. Methods: Scopus, PubMed, Embase, Cochrane, Web of science databases, and Google Scholar and manual screening of retrieved references were systematically searched from their inception dates to 24 March 2020 by extracting the effect size (Odds ratios (OR) and relative risk (RR) in each study. To present the forest plot of effect of metformin on each cancer, Stata version 14.2 was used. Results: This study included 36 meta‑analysis studies and 620 original research studies (26 randomized control trials studies and 594 observational studies (cohort, case–control)) covering 15 different cancers. Overall, metformin medication prevented different cancers, including ovarian cancer (OR = 0.76, 95% CI: 0.62,0.93), cervical cancer (OR = 0.60, 95% CI: 0.43, 0.83), endometrial cancer (OR = 1.05, 95% CI: 0.82,1.35), liver cancer (OR = 0.59, 95% CI: 0.47,0.74), pancreatic cancer (OR = 0.59, 95%CI 0.50,0.69), head and neck cancer (OR = 0.71, 95% CI: 0.61,0.83), stomach cancer (OR = 0.72, 95% CI: 0.26,1.99), colorectal cancer (OR = 0.73, 95% CI: 0.59,0.91), colorectal adenoma cancer (OR = 0.75, 95% CI: 0.65,0.86), colon cancer (OR = 0.79, 95% CI: 0.69,0.91), esophagus cancer (OR = 0.90, 95% CI: 0.83,0.98), lung cancer (OR = 0.92, CI95%:0.85,0.99), breast cancer (OR = 0.93, 95% CI: 0.84,1.02), prostate cancer (OR = 0.94, 95% CI: 0.85‑1.04), and bladder cancer (OR = 0.94 95% CI: 0.64,1.38). Conclusions: Treatment with metformin can significantly decrease the chance of all cancers with larger preventive effect on hepatocellular carcinoma and smaller preventive effect on lung and breast cancers.

Keywords


Diabetes mellitus; meta‑analysis; metformin; neoplasms; review

Full Text:

PDF

References


Khazaie H, Najafi F, Hamzeh B, Chehri A, Rahimi‑Movaghar A,

Amin‑Esmaeili M, et al. Cluster analysis of psychiatric profile,

its correlates, and using mental health services among the young

people aged 15–34: Findings from the first phase of Iranian

youth cohort in Ravansar. Soc Psychiatry Psychiatr Epidemiol

;53:1339‑48.

Silidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP.

Type 2 diabetes andcancer: Umbrella review of meta‑analyses of

observational studies. BMJ 2015;350:g7606. doi: 10.1136/bmj.

g7607.

Sun W, Lu J, Wu S, Bi Y, Mu Y, Zhao J, et al. Association

of insulin resistance with breast, ovarian, endometrial and

cervical cancers in non‑diabetic women. Am J Cancer Res

;6:2334‑44.

Macaskill P, Walter SD, Irwig L. A comparison of methods

to detect publication bias in meta‑analysis. Stat Med

;20:641‑54.

Evans JM, Donnelly LA, Emslie AM‑Smith, Alessi DR,

Morris AD. Metformin and reduced risk of cancer in diabetic

patients. BMJ 2005;330:1304‑5.

Cho SM, Lee SG, Kim HS, Kim JH. Establishing pediatric

reference intervals for 13 biochemical analytes derived from

normal subjects in a pediatric endocrinology clinic in Korea.

Clin Biochem 2014;47:268‑71.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A.

Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87‑108.

Sahra IB, Le Marchand‑Brustel Y, Tanti JF, Bost F. Metformin in

cancer therapy: A new perspective for an old antidiabetic drug?

Mol Cancer Ther 2010;9:1092‑9. Pollak M. Metformin and

pancreatic cancer: A clue requiring investigation. Clin Cancer

Res 2012;18:2723‑5.

Tseng CH. Metformin reduces thyroid cancer risk in Taiwanese

patients with type 2 diabetes. PLoS One 2014;9:e109852. doi:

1371/journal.pone. 0109852.

Tseng CH. Metformin may reduce oral cancer risk in patients

with type 2 diabetes. Oncotarget 2016;7:2000‑8.

Tseng CH. Metformin reduces gastric cancer risk in patients with

type 2 diabetes mellitus. Aging (Albany NY) 2016;8:1636‑49.

Tseng CH. Metformin may reduce bladder cancer risk in

Taiwanese patients with type 2 diabetes. Acta Diabetol

;51:295‑303.

Tseng CH. Metformin significantly reduces incident prostate

cancer risk in Taiwanese men with type 2 diabetes mellitus. Eur

J Cancer 2014;50:2831‑7.

Tseng CH. Metformin may reduce breast cancer risk in

Taiwanese women with type 2 diabetes. Breast Cancer Res Treat

;145:785‑90.

Tseng CH. Metformin and endometrial cancer risk in Chinese

women with type 2 diabetes mellitus in Taiwan. Gynecol Oncol

;138:147‑53.

Tseng CH. Metformin reduces ovarian cancer risk in Taiwanese

women with type 2 diabetes mellitus. Diabetes Metab Res Rev

;31:619‑26.

Tseng CH. Metformin use and cervical cancer risk in female

patients with type 2 diabetes. Oncotarget 2016;7:59548‑55.

Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A,

Bonanni B, et al. Metformin and cancer risk in diabetic patients:

A systematic review and meta‑analysis. Cancer Prev Res (Phila)

;3:1451‑61.

Shuai Y, Li C, Zhou X. The effect of metformin on gastric

cancer in patients with type 2 diabetes: A systematic review and

meta‑analysis. Clin Transl Oncol 2020;22:1580‑90.

Chen CB, Eskin M, Eurich DT, Majumdar SR, Johnson JA.

Metformin, Asian ethnicity and risk of prostate cancer in type 2

diabetes: A systematic review and meta‑analysis. BMC Cancer

;18:65.

Deng M, Lei S, Huang D, Wang H, Xia S, Xu E, et al.

Suppressive effects of metformin on colorectal adenoma incidence and malignant progression. Pathol Res Pract

;216:152775. doi: 10.1016/j.prp. 2019.152775.

Wen Q, Zhao Z, Wen J, Zhou J, Wu J, Lei S, et al. The

association between metformin therapy and risk of gynecological

cancer in patients: Two meta‑analyses. Eur J Obstet Gynecol

Reprod Biol 2019;237:33‑41.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA

Group. Preferred reporting items for systematic reviews

and meta‑analyses: The PRISMA statement. PLOS Med

;6:e1000097. doi: 10.1371/journal.pmed. 1000097.

Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N,

Hamel C, et al. Development of AMSTAR: A measurement tool

to assess the methodological quality of systematic reviews. BMC

Med Res Methodol 2007;7:10. doi: 10.1186/1471‑2288‑7‑10.

Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, et al.

Reduced risk of colorectal cancer with metformin therapy in

patients with type 2 diabetes: A meta‑analysis. Diabetes Care

;34:2323‑8.

Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic

patients treated with metformin: A systematic review and

meta‑analysis. PLoS One 2012;7:e33411.

Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE. Metformin

for liver cancer prevention in patients with type 2 diabetes:

A systematic review and meta‑analysis. J Clin Endocrinol Metab

;97:2347‑53.

Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT.

Metformin and breast cancer risk: A meta‑analysis and critical

literature review. Breast Cancer Res Treat 2010;135:639‑46.

Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F,

Nicolucci A. Metformin therapy and risk of cancer in

patients with type 2 diabetes: Systematic review. PLoS One

;8:e71583.

Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS.

Metformin and sulfonylureas in relation to cancer risk in

type II diabetes patients: A meta‑analysis using primary data of

published studies. Metabolism 2013;62:922‑34.

Zhang ZJ, Bi Y, Li S, Zhang Q, Zhao G, Guo Y, et al. Reduced

risk of lung cancer with metformin therapy in diabetic patients:

A systematic review and meta‑analysis. Am J Epidemiol

;180:11‑4.

Nie Z, Zhu H, Gu M. Reduced colorectal cancer incidence in

type 2 diabetic patients treated with metformin: A meta‑analysis.

Pharm Biol 2016;54:2636‑42.

Li L, Qi X, Xu M, Ding X, Zhou X, Zhang C, et al. The effects

of metformin on ovarian cancer: An updated systematic review

and meta‑analysis. Int J Clin Exp Med 2016;9:17559‑68.

Rokkas T and Portincasa P. Colon neoplasia in patients with

type 2 diabetes on metformin: A meta‑analysis. Eur J Intern Med

;33:60‑6.

Ma S, Zheng Y, Xiao Y, Zhou P, Tan H. Meta‑analysis of studies

using metformin as a reducer for liver cancer risk in diabetic

patients. Medicine (Baltimore) 2017;96:e6888.

Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus

and risk of hepatocellular carcinoma: A systematic review and

meta‑analysis. Diabetes Metab Res Rev 2012;28:109‑22.

Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR,

Chari ST. Anti‑diabetic medications and risk of pancreatic cancer

in patients with diabetes mellitus: A systematic review and

meta‑analysis. Am J Gastroenterol 2013;108:510‑9.

Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Antidiabetic

medications and the risk of colorectal cancer in patients with

diabetes mellitus: A systematic review and meta‑analysis. Cancer

Epidemiol Biomarkers Prev 2013;22:2258‑68.

Singh S, Singh PP, Singh AG, Murad MH, Sanchez W.

Anti‑diabetic medications and the risk of hepatocellular cancer:

A systematic review and meta‑analysis. Am J Gastroenterol

;108:881‑91.

Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Metformin and

reduced risk of hepatocellular carcinoma in diabetic patients:

A meta‑analysis. Scand J Gastroenterol 2013;48:78‑87.

Wang Z, Lai ST, Xie L, Zhao JD, Ma NY, Zhu J, et al.

Metformin is associated with reduced risk of pancreatic cancer in

patients with type 2 diabetes mellitus: A systematic review and

meta‑analysis. Diabetes Res Clin Pract 2014;106:19‑26.

Nie SP, Chen H, Zhuang MQ, Lu M. Anti‑diabetic medications

do not influence risk of lung cancer in patients with diabetes

mellitus: A systematic review and meta‑analysis. Asian Pac J

Cancer Prev 2014;15:6863‑9.

Wu L, Zhu J, Prokop LJ, Murad MH. Pharmacologic therapy of

diabetes and overall cancer risk and mortality: A meta‑analysis

of 265 studies. Sci Rep 2015;5:10147. doi: 10.1038/srep10147.

Herrán SC, Jané‑Salas E, Estrugo Devesa A, López‑López J.

Protective effects of metformin, statins and anti‑inflammatory

drugs on head and neck cancer: A systematic review. Oral Oncol

;85:68‑81.

Ghiasi B, Sarokhani D, Najafi F, Motedayen M, Dehkordi AH.

The relationship between prostate cancer and metformin

consumption: A systematic review and meta‑analysis study. Curr

Pharm Des 2019;25:1021‑9.

Tang GH, Satkunam M, Pond GR, Steinberg GR, Blandino G,

Schünemann HJ, et al. Association of metformin with breast

cancer incidence and mortality in patients with type II diabetes:

A GRADE‑assessed systematic review and meta‑analysis. Cancer

Epidemiol Biomarkers Prev 2018;27:627‑35.

Yao L, Liu M, Huang Y, Wu K, Huang X, Zhao Y, et al.

Metformin use and lung cancer risk in diabetic patients:

A systematic review and meta‑analysis. Dis Markers

;2019:6230162. doi: 10.1155/2019/6230162.

Feng Z, Zhou X, Liu N, Wang J, Chen X, Xu X. Metformin

use and prostate cancer risk: A meta‑analysis of cohort studies.

Medicine 2019;98:e14955.

Moradi‑Joo M, Mohabbat‑Bahar S, Heidari S, Davoodi SH,

GarehSheyklo S, Akbari ME. Metforminversus sulfonylureain

breast cancer risk of diabetic patients: A systematic review and

meta‑analysis. Iran J Cancer Prev 2016;9:e5971. doi: 10.17795/

ijcp‑5971.

Liu F, Yan L, Wang Z, Lu Y, Chu Y, Li X, et al. Metformin

therapy and risk of colorectal adenomas and colorectal cancer

in type 2 diabetes mellitus patients: A systematic review and

meta‑analysis. Oncotarget 2017;8:16017‑26.

Tian J, Liang Y, Qu P. Antidiabetic medications and the risk of

endometrial cancer in patients. Gynecol Invest 2019;84:455‑62.

Mekuria AN, Ayele Y, Tola A, Mishore KM. Monotherapy

with metformin versus sulfonylureas and risk of cancer in

type 2 diabetic patients: A systematic review and meta‑analysis.

J Diabetes Res 2019;2019:7676909. doi: 10.1155/2019/7676909.

Chu D, Wu J, Wang K, Zhao M, Wang C, Li L, et al. Effect

of metformin use on the risk and prognosis of endometrial

cancer: A systematic review and meta‑analysis. BMC Cancer

;18:438. doi: 10.1186/s12885‑018‑4334‑5.

Hu H, Fang Y, Zhou X, Gong L, Liu L, Wang W, et al.

Relationship of metformin with the risk of pancreatic cancer

in patients with type 2 diabetes: A meta‑analysis. Biomed Res

;28:4439.

Shi J, Liu B, Wang H, Zhang T, Yang L. Association of

metformin use with ovarian cancer incidence and prognosis:A systematic review and meta‑analysis. Int J Gynecol Cancer

;29:140‑6.

Chai S, Yu S, Yang Z, Wu S, Gao L, Wang H, et al. Effect of

incretin‑based therapies on cancers of digestive system among

595 patients with type 2 diabetes mellitus: A systematic

review and network meta‑analysis combining 84 trials with a

median duration of 30 weeks. BMJ Open Diabetes Res Care

;7:e000728. doi: 10.1136/bmjdrc‑2019‑000728.

Grenader T, Goldberg A, Shavit L. Metformin as an addition

to conventional chemotherapy in breast cancer. J Clin Oncol

;27:e259. doi: 10.1200/JCO.2009.25.4110.

Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ,

Zhao F, et al. Systemic treatment with the antidiabetic drug

metformin selectively impairs p53‑ deficient tumor cell growth.

Cancer Res 2007;67:6745‑52.

Zhuang Y, Miskimins WK. Cell cycle arrest in metformin treated

breast cancer cells involves activation of AMPK, downregulation

of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal

;3:18. doi: 10.1186/1750‑2187‑3‑18.

Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin

selectively targets cancer stem cells, and acts together with

chemotherapy to block tumor growth and prolong remission.

Cancer Res 2009;69:7507‑11.

Li K, Si‑Tu J, Qiu J, Lu L, Mao Y, Zeng H, et al. Statin and

metformin therapy in prostate cancer patients with hyperlipidemia

who underwent radiotherapy: A population‑based cohort study.

Cancer Manag Res 2019;11:1189‑97.

Gallagher EJ, LeRoith D. Obesity and diabetes: The increased risk

of cancer and cancer‑related mortality. Physiol Rev 2015;95:727‑48.

Zheng LY, Zou DJ. Metformin inhibits proliferation and colony

formation ability through AMP‑activated protein kinase in

hepatocellular carcinoma cells. Diabetes 2012;61:A457.

Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M,

Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in

mice independently of the LKB1/AMPK pathway via a decrease

in hepatic energy state. J Clin Invest 2010;120:2355‑69.

Sośnicki S, Kapral M, Węglarz L. Molecular targets of

metformin antitumor action. Pharmacol Rep 2016;68:918‑25.

Fidan E, Onder Ersoz H, Yilmaz M, Yilmaz H, Kocak M,

Karahan C, et al. The effects of rosiglitazone and metformin on

inflammation and endothelial dysfunction in patients with type 2

diabetes mellitus. Acta Diabetol 2011;48:297‑302.

Chen HH, Lin MC, Muo CH, Yeh SY, Sung FC, Kao CH.

Combination therapy of metformin and statin may decrease

hepatocellular carcinoma among diabetic patients in Asia.

Medicine 2015;94:e1013. doi: 10.1097/MD.0000000000001013.